EGFR and non-small cell lung carcinoma: Osimertinib, a third-generation EGFR tyrosine kinase inhibitor (TKI), is the standard of care for the first-line treatment of advanced non-small cell lung cancer (NSCLC) with EGFR-activating mutations and is initially approved for the treatment of NSCLC in patients who develop the EGFR T790M mutation after treatment with a first- or second-generation EGFR-TKIs [1].